Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples